Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Autor:	P. Moreau, Maria Gavriatopoulou, Reuben Benjamin, Tuphan Kanti Dolai, Moshe Yair Levy, Vadim A Doronin, Paul G. Richardson, Hang Quach, Maryana Simonova, Ludek Pour, Don A. Stevens, Halyna Pylypenko, Thierry Facon, Xavier Leleu, Melina Arazy, Christopher P. Venner, Larry D. Anderson, Ashraf Z. Badros, Dinesh Kumar Sinha, Nizar J. Bahlis, Maria-Victoria Mateos, Jatin P. Shah, Sebastian Grosicki, Michele Cavo, Ganna Usenko, Yi Chai, Ivan Spicka, Sundar Jagannath, Roman Hájek, Meletios A. Dimopoulos, Michael Kauffman, Iryna Kriachok, Mamta Garg, Sharon Shacham, Holger W. Auner, Sosana Delimpasi
Přispěvatelé:	Auner H.W., Gavriatopoulou M., Delimpasi S., Simonova M., Spicka I., Pour L., Dimopoulos M.A., Kriachok I., Pylypenko H., Leleu X., Doronin V., Usenko G., Hajek R., Benjamin R., Dolai T.K., Sinha D.K., Venner C.P., Garg M., Stevens D.A., Quach H., Jagannath S., Moreau P., Levy M., Badros A., Anderson L.D., Bahlis N.J., Facon T., Mateos M.V., Cavo M., Chai Y., Arazy M., Shah J., Shacham S., Kauffman M.G., Richardson P.G., Grosicki S.
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	Oncology Male Gastrointestinal Diseases Kaplan-Meier Estimate Severity of Illness Index Dexamethasone Bortezomib 0302 clinical medicine Retrospective Studie Antineoplastic Combined Chemotherapy Protocols Hydrazine Multicenter Studies as Topic Age Factor Multiple myeloma Randomized Controlled Trials as Topic Aged 80 and over Frailty Age Factors Peripheral Nervous System Diseases Hematology Middle Aged Progression-Free Survival Hydrazines Tolerability 030220 oncology & carcinogenesis Female Multiple Myeloma medicine.drug Human Adult medicine.medical_specialty Gastrointestinal Disease Subgroup analysis Drug Administration Schedule 03 medical and health sciences Internal medicine Severity of illness medicine Humans Progression-free survival Lenalidomide Retrospective Studies Aged Antineoplastic Combined Chemotherapy Protocol business.industry Hematologic Disease Triazoles medicine.disease Hematologic Diseases Clinical Trials Phase III as Topic Peripheral Nervous System Disease business 030215 immunology
Popis:	Elderly and frail patients with multiple myeloma (MM) are more vulnerable to the toxicity of combination therapies, often resulting in treatment modifications and suboptimal outcomes. The phase 3 BOSTON study showed that once-weekly selinexor and bortezomib with low-dose dexamethasone (XVd) improved PFS and ORR compared with standard twice-weekly bortezomib and moderate-dose dexamethasone (Vd) in patients with previously treated MM. This is a retrospective subgroup analysis of the multicenter, prospective, randomized BOSTON trial. Post hoc analyses were performed to compare XVd versus Vd safety and efficacy according to age and frailty status (
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98a9cd6d43172e2122cda2b0568bd327 https://hdl.handle.net/11585/865006 Zobrazit plný text záznamu